SIRION Biotech, Denali Therapeutics to Develop New AAV Vectors to Help Treat ALS
SIRION Biotech and Denali Therapeutics have signed a new licensing agreement to develop a new generation of adeno-associated virus (AAV) vectors, harmless viruses used as vehicles to deliver gene therapies, to allow therapies to reach into the central nervous system (CNS) of people with amyotrophic lateral sclerosis (ALS). The…